NightHawk Biosciences announced its Scorpius BioManufacturing subsidiary has been awarded a project to support a preclinical program for a U.S. based biotech company. The initial project value exceeds one million dollars, with the potential to exceed several million dollars over the next two years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1838 USD | -4.27% | +14.30% | -58.26% |
Apr. 26 | Scorpius Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Apr. 23 | Scorpius Holdings Gets Non-Compliance Notice From NYSE American | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-58.26% | 6.62M | |
+12.66% | 9.06B | |
-12.75% | 4.96B | |
+42.38% | 4.47B | |
+5.23% | 3.9B | |
+20.51% | 2.41B | |
-19.05% | 2.41B | |
-28.72% | 2.23B | |
+11.13% | 2.02B | |
+3.94% | 1.65B |
- Stock Market
- Equities
- SCPX Stock
- News Scorpius Holdings, Inc.
- Nighthawk?S Scorpius Biomanufacturing Subsidiary Commences Work on Preclinical Program for New Client